乐普生物-B(02157.HK)首次实现盈利 预计上半年利润不少于2400万元

Core Viewpoint - The company, Lepu Biopharma-B (02157.HK), is expected to report a profit of no less than RMB 24 million for the six months ending June 30, 2025, marking its first profitable period after a loss of approximately RMB 197 million in the same period last year [1] Financial Performance - The significant turnaround from loss to profit is attributed to substantial revenue growth [1] - Key contributors to revenue include licensing income from a collaboration with ArriVent BioPharma, Inc. regarding MRG007 and increased sales of the product Putili (普特利单抗注射液) [1]